Prospective single-arm protocol of carvedilol in children with ventricular dysfunction

Area of Science:

• Pediatric Cardiology
• Cardiovascular Pharmacology
• Heart Failure Management

Background:

• Pediatric heart failure requires effective therapeutic strategies.
• Carvedilol is a beta-blocker with alpha-blocking activity, showing promise in adult heart failure.
• Limited data exists on carvedilol's use in pediatric populations with heart failure.

Purpose of the Study:

• To assess the safety and efficacy of carvedilol in pediatric patients with stable, moderate heart failure.
• To evaluate carvedilol's impact on echocardiographic parameters and clinical outcomes.
• To compare outcomes of treated pediatric patients with historical untreated controls.

Main Methods:

• A single-arm, prospective drug trial involving 20 pediatric patients (3 months to 17 years) with ejection fraction <40%.
• Patients received carvedilol, with doses uptitrated to 0.8 mg/kg/day or maximum tolerated dose.
• Echocardiographic function and clinical endpoints were assessed at baseline and 6 months, compared to historical controls.

Main Results:

• The ejection fraction in the treated dilated cardiomyopathy (DCM) group significantly improved (31% to 40%, p=0.04).
• Treated DCM patients showed a greater median increase in ejection fraction compared to untreated controls (7% vs 0%, p=0.05).
• Time to death or transplant trended longer in treated patients (p=0.07), with no significant difference in severe decline or clinical change.

Conclusions:

• Adjunct carvedilol therapy in pediatric DCM patients improved ejection fraction compared to controls.
• Carvedilol demonstrated a trend towards delaying adverse events like death or transplant in this cohort.
• The study supports carvedilol as a potential therapeutic option for pediatric heart failure.